Kestra Medical (KMTS) CFO receives 44,118 performance-based shares

Rhea-AI Filing Summary

Kestra Medical Technologies Chief Financial Officer Mahboob Vaseem acquired 44,118 Common Shares on July 15, 2026, at 0.0000 per share, upon vesting of performance-based RSUs granted on July 17, 2025 after achievement of specified goals. Following this award, he directly owns 112,079 Common Shares.

Insider Trade Summary

Net Buyer: 44,118 shares

Net Buy 1 txn

Insider Mahboob Vaseem

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Grant/Award	Common Shares F1	44,118	$0.00	--

Holdings After Transaction: Common Shares — 112,079 shares (Direct)

Footnotes (1)

1. F1. Represents common shares earned with respect to an award of performance-based RSUs ("PSUs") granted on July 17, 2025, as determined based on the Issuer's achievement of specified performance goals. 100% of the PSUs vested on July 15, 2026.

Key Figures

Shares acquired: 44,118 common shares Award price per share: 0.0000 per share Total holdings after transaction: 112,079 common shares +2 more

5 metrics

Shares acquired 44,118 common shares Grant/award acquisition on July 15, 2026

Award price per share 0.0000 per share Common shares issued from vested performance-based RSUs

Total holdings after transaction 112,079 common shares Direct ownership following July 15, 2026 award

PSU grant date July 17, 2025 Original performance-based RSU award date

PSU vesting date July 15, 2026 100% of PSUs vested based on performance goals

Key Terms

performance-based RSUs, PSUs, vested

3 terms

performance-based RSUs financial

"award of performance-based RSUs ("PSUs") granted on July 17, 2025"

Performance-based restricted stock units (RSUs) are promises to deliver company shares to employees only if the business meets specific goals, such as revenue, profit, stock-price targets, or strategic milestones. For investors, they matter because they change future share supply and align management incentives with company results—like a salesperson whose bonus only pays out when sales targets are hit—so they can affect earnings, dilution, and confidence in leadership.

PSUs financial

"100% of the PSUs vested on July 15, 2026"

PSUs are company shares promised to employees or executives that only become actual stock if the business hits specific performance targets over a set period. For investors, PSUs matter because they link pay to measurable outcomes — similar to a conditional bonus that converts into ownership — which can influence management decisions, dilution of shares, and signals about confidence in future results.

vested financial

"100% of the PSUs vested on July 15, 2026"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 07/17/2026 - 05:51 PM Accepted by SEC EDGAR 07/17/2026 - 05:50 PM Learn about SEC filing dates

FAQ

What transaction did Kestra Medical (KMTS) CFO Mahboob Vaseem report on this Form 4?

He reported receiving 44,118 common shares granted at 0.0000 per share as Kestra Medical (KMTS) Chief Financial Officer. The shares were earned from performance-based RSUs granted on July 17, 2025, which vested in full on July 15, 2026 after specified goals were achieved.

How many Kestra Medical (KMTS) shares does the CFO own after this Form 4 transaction?

After the award, Mahboob Vaseem directly owns 112,079 common shares of Kestra Medical (KMTS). This figure reflects his total reported direct holdings of the company’s common shares immediately following the July 15, 2026 vesting and share issuance event.

What was the source and timing of the 44,118 Kestra Medical (KMTS) shares reported by the CFO?

The 44,118 shares arose from performance-based RSUs granted on July 17, 2025. Based on Kestra Medical (KMTS) achieving specified performance goals, 100% of these PSUs vested and converted into common shares on July 15, 2026.

Did Mahboob Vaseem pay for the 44,118 Kestra Medical (KMTS) shares he acquired?

No cash payment was reported; the transaction price was 0.0000 per share. The 44,118 Kestra Medical (KMTS) common shares were issued upon vesting of previously granted performance-based RSUs, functioning as equity compensation rather than an open-market purchase.

What type of security was involved in Mahboob Vaseem’s Kestra Medical (KMTS) Form 4?

The reported transaction involved non-derivative Common Shares of Kestra Medical (KMTS). These shares were delivered when performance-based RSUs (PSUs) vested in full, converting into ordinary common equity rather than remaining as derivative or option-style instruments.

How were the performance conditions structured for the Kestra Medical (KMTS) PSUs reported by the CFO?

The award consisted of performance-based RSUs (PSUs) that were earned based on Kestra Medical’s achievement of specified performance goals. According to the disclosure, 100% of these PSUs vested on July 15, 2026, triggering issuance of 44,118 common shares.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Mahboob Vaseem

(Last) (First) (Middle)

3933 LAKE WASHINGTON BLVD NE, SUITE 200

(Street)

KIRKLAND WASHINGTON 98033

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
KESTRA MEDICAL TECHNOLOGIES, LTD. [ KMTS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Shares	07/15/2026		A		44,118(1)	A	$0	112,079	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents common shares earned with respect to an award of performance-based RSUs ("PSUs") granted on July 17, 2025, as determined based on the Issuer's achievement of specified performance goals. 100% of the PSUs vested on July 15, 2026.

	/s/ Traci S. Umberger as attorney-in-fact for Vaseem Mahboob	07/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)